Clinical Trial Update: Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating recombinant human interleukin-7 (CYT107) for tumor clearance and immune reconstitution in multiple myeloma patients after auto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYT107 (CYT107)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING